



Smruthi Organics Limited

Date: 06th August, 2022

To
Corporate Relation Department
BSE Limited
P. J. Tower, Dalal Street,
Mumbai – 400 001.

To
Listing Department
Metropolitan Stock Exchange of India Ltd
4th floor, Vibgyor tower,
Opposite Trident Hotel,
Bandra- Kurla Complex, Mumbai - 400098

Scrip Code: 540686

Subject: Outcome of Board meeting of the Company held today i.e. Saturday, 06th August, 2022

Dear Sir,

Kindly note that the Board of Directors of the Company has, in its meeting held today i.e. on Saturday, 06th August, 2022 ("said meeting"), considered and approved the Unaudited Financial Results of the Company for the first quarter ended 30th June, 2022.

Further, pursuant to the applicable provisions of SEBI Listing Regulations, please find enclosed herewith: - (i) the Unaudited Financial Results; and (ii) Limited Review Report dated 06th August, 2022, issued by the Statutory Auditors of the Company w.r.t. the Unaudited Financial Results and taken on record by the Board of Directors of the Company.

Necessary arrangements have been made for publishing the Unaudited Financial results in the newspapers, in the prescribed formats of SEBI Listing Regulations.

Kindly take on record the above information and acknowledge.

The meeting commenced at 10:00 a.m and concluded at 10:50 a.m

For Smruthi Organics Limited

Urvashi Khanna
Company Secretary



Smruthi Organics Limited


Registered & Corporate Office.: 165-A, Balaji Bhavan, 1st Floor, Railway Lines, Solapur-413001 (Maharashtra)


CIN :- L24119PN1989PLC052562

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2022

Rs. In Lakhs

Sr.No.	Particulars	Quarter Ended			Year ended
		Current Year	Previous Year	Previous Year	Previous Year
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		(Un-audited)	(Audited)	(Un-audited)	(Audited)
1	Income from operations				
	a) Revenue from operations (Net)	2907.28	3547.36	3089.64	13337.15
	b) Other income	3.10	9.53	18.05	58.33
	Total Revenue from operations & other Income (a+b)	2910.38	3556.89	3107.69	13395.48
2	Expenses				
	a) Cost of materials consumed	2192.84	2018.19	1858.99	8180.18
	b) Purchases of Traded Goods	7.43	3.85	9.71	34.25
	c) Changes in inventories of finished goods & work-in-progress	(356.50)	267.22	(41.51)	(208.16)
	d) Employee benefit expenses	362.23	283.61	341.29	1372.60
	e) Finance Costs	11.93	12.32	22.66	98.36
	f) Depreciation and amortisation expenses	111.49	110.63	105.00	425.63
	g) Other expenses	529.81	609.27	477.41	2115.44
	TOTAL Expenses (a+b+c+d+e+f+g)	2859.23	3305.09	2773.55	12018.30
3	Profit/(Loss) before exceptional items and tax (1-2)	51.15	251.80	334.14	1377.18
4	Exceptional items	-	-	-	-
5	Profit/ (loss) before tax (3 - 4)	51.15	251.80	334.14	1377.18
6	Tax expense				
	a) Current Income Tax	22.14	66.31	83.19	356.00
	b) MAT Credit Entitlement	-	-	0.00	-
	c) Defered Tax (Asset) / Liability	(1.25)	12.35	(2.39)	(17.00)
	Total Tax Expenses (a+b+c)	20.89	78.66	80.80	339.00
7	Net Profit/(Loss) for the period (5 - 6)	30.25	173.14	253.34	1038.18
8	Other Comprehensive Income				
	i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss.	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-
.9	Total comprehensive income (7 + 8)	30.25	173.14	253.34	1038.18
10	Paid-up equity share capital (Face value of Rs.10/- each)	1144.63	1144.63	1144.63	1144.63
11	Earnings per equity share (not annualised)				
	a) Basic	0.26	1.51	2.21	9.07
	b) Diluted	0.26	1.51	2.21	9.07



	Notes:
1	The Operations of the Company constitute Bulk Drugs, Drug Intermediates as a major business segment and Formulations division as a minor segment.
2	The Statutory Auditor have carried out the Limited Review of Un-audited financial results of the Company for the first quarter ended June 30, 2022
3	The above financials were reviewed by the Audit Committee and Approved by the Board of Directors at meeting held on August 06 2022.
4	Revenue from Operations (Sales) for the first quarter ended June 30, 2022 is net of Goods and Service Tax(GST).
5	The results include sale of Rs 3.52 lakhs and loss of Rs.38.53 lakhs incurred by the Formulation Division.
6	The financial results are prepared in accordance with the Indian Accounting Standards (Ind AS) 108 as prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
8	Previous period's figures have been regrouped / rearranged wherever necessary to confirm to the current period's classification.
	<div style="display: flex; justify-content: space-between; align-items: flex-start;"> <div style="width: 30%;"> <p>Place : Solapur Date : August, 6,2022</p> </div> <div style="width: 30%; text-align: center;">  </div> <div style="width: 30%; text-align: right;"> <p><i>E. Purushotham</i> E. PURUSHOTHAM CHAIRMAN & MANAGING DIRECTOR DIN 00033588</p> </div> </div>



Smruthi Organics Limited

Date: 06-08-2022

To
Corporate Relation Department
BSE Limited
P. J. Tower, Dalal Street,
Mumbai – 400 001.

To
Listing Department
Metropolitan Stock Exchange of India Ltd
4th floor, Vibgyor tower,
Opposite Trident Hotel,
Bandra- Kurla Complex, Mumbai – 400098

Subject: Non-applicability of Reg. 32 of SEBI (LODR) Regulations, 2015 (Statement of Deviation or Variation for proceeds of public issue, rights issue, preferential issue, QIP)

Dear Sir

Please note that the Statement of Deviation or Variation for proceeds of public issue, rights issue, preferential issue, QIP to be given along with quarterly results as required under Reg. 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company as the company has not issued shares by way of public issue, rights issue, preferential issue, QIP etc during the quarter.


Kindly take the above on record.

Thanking You

Yours Faithfully

For Smruthi Organics Limited


Urvasi Khanna
Company Secretary



Annex 2

Limited Review Report on unaudited Standalone Financial Results of Smruthi Organics Limited for three month ended 30th June 2022 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We have reviewed the accompanying statement of unaudited financial results of Smruthi Organics Limited for the period ended 30th June 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place : Solapur
Date : 06.08.2022
UDIN : 22048890AOKJEV3502

N.R. Waghchaure & Associates
Chartered Accountants

FRN – 114999W


N.R. Waghchaure

Proprietor

M.No. 048890